NCT06200974|Recruiting
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
BrachyTRACKS
Loading search results
BrachyTRACKS
Sponsor study identifier
observational
100
1 country
1
Study Start
February 1, 2024
Actual (reported)Primary Completion
March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 1, 2038
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy. This study takes a multi-omics approach to study the mechanism of action of HDR brachytherapy through metabolomics, immunological, transcriptomics, and spectroscopic profiling. The results of this study will clarify the optimal dose for HDR prostate brachytherapy by documenting the dose-response relationship seen in the changing tumor metabolites after HDR brachytherapy and investigate the immunogenicity of HDR brachytherapy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 1, 2038
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 13, 2023
Actual (reported)January 11, 2024
Actual (reported)February 1, 2024
Actual (reported)March 1, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
February 1, 2038
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Changes in biomolecular composition in prostate cancer after high dose rate prostate brachytherapy as measured by Raman spectroscopy
We will report the most important biomolecules altered by radiation (importance determined by the relative change of the score as a component of the Raman spectrum before and after radiation) and whether that observed change corelates with PSA outcome for each individual patient
1-2 weeks, PSA: 0-10 years
ctDNA detection following HDR Brachytherapy
Number of patients with a (transient) increase in circulating tumor DNA after a single fraction of high-dose rate prostate brachytherapy will be reported
0-4 weeks
Immunogenicity against somatic mutations
single cell-RNA sequencing of immune cell populations before and after 13.5 Gray of radiation will be used for each individual patient and the number of patients with a change in gene expression (through activation or inactivation) will be reported
0-4 weeks
Response Outcome: PSA Nadir
0-10 years
Response Outcome: 4-year PSA
0-4 years
Acute and long term toxicity
0-10 years
Radiation. High dose rate prostate brachytherapy is delivered under anesthesia in 2 procedures, 1-2 weeks apart. HDR brachytherapy is also accomplished as an out-patient.
Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Patients diagnosed with localized prostate cancer suitable for brachytherapy as monotherapy.
British Columbia Cancer Center for the Southern Interior
Kelowna, British Columbia, V1Y 5L3, Canada
blood and tissue
Juanita M Crook, MD
Radiation Oncologist
First Submitted
December 13, 2023
First Posted
January 11, 2024
Study Start
February 1, 2024
Actual (reported)Primary Completion
March 1, 2028
EstimatedPSMA-Guided Ablation of the Prostate
Gut microbiome
To determine microbial composition before brachytherapy and report for the individual patient whether diversity in composition is changed or skewed after treatment with high dose rate prostate brachytherapy. Second assessment is after completion of both fractions of radiation. Number of patients with alteration in microbial composition will be reported.
0-4 weeks
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
February 1, 2038
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
February 2, 2026
Record last verified: 2026-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: